KIT
Mast/stem cell growth factor receptor Kit
As of the edition of 20 October 2026, KIT (mast/stem cell growth factor receptor Kit, UniProt P10721) has 36 drugs tested at it and 41 companies on the list, 14 on route A and 5 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P10721
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 65
- Disease areas
- Cancer; Digestive system; Urinary and reproductive; Pregnancy and women's health; Lungs and airways; Skin and connective tissue; Blood and lymph; Hormones
- Registered trials of its drugs
- 1,935
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 9 |
| Active | 10 |
| Went quiet | 7 |
| Stopped | 10 |
| Total | 36 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Catequentinib | Active | Phase 4 | none listed |
| Sunitinib | Marketed | Phase 4 | none listed |
| Regorafenib | Marketed | Phase 4 | Ends 2032 |
| Pazopanib | Marketed | Phase 4 | none listed |
| Cediranib | Stopped | Phase 3 | none listed |
| Famitinib | Stopped | Phase 3 | none listed |
| Dovitinib | Active | Phase 3 | none listed |
| Midostaurin | Marketed | Phase 3 | none listed |
| Quizartinib | Marketed | Phase 3 | Ends 2030 |
| Tivozanib | Marketed | Phase 3 | Ends 2028 |
| Masitinib | Stopped | Phase 3 | none listed |
| Vatalanib | Went quiet | Phase 3 | none listed |
12 of 36 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 14 |
| Route B | 5 |
| Engaged | 20 |
| Undetermined | 2 |
| Total on the list | 41 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| AstraZeneca | Route A |
| Jiangsu HengRui Medicine | Route A |
The other 38 companies at KIT
In the product41 companies in all; 38 are not named here, and no score is.
See the 41 companies at KIT, ranked, with the facts behind eachRequest access. Nothing is shown until you do.